BACKGROUND: The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority for control of a future outbreak. METHODS: In this phase 1 study, we administered a single dose of the chimpanzee adenovirus 3 (ChAd3) vaccine encoding the surface glycoprotein of Zaire ebolavirus (ZEBOV) to 60 healthy adult volunteers in Oxford, United Kingdom. The vaccine was administered in three dose levels--1×10(10) viral particles, 2.5×10(10) viral particles, and 5×10(10) viral particles--with 20 participants in each group. We then assessed the effect of adding a booster dose of a modified vaccinia Ankara (MVA) strain, encoding the same Ebola virus glycoprotein, in 30 of the 60 participants and evaluated a reduced prime-boost interval in another 16 participants. We also compared antibody responses to inactivated whole Ebola virus virions and neutralizing antibody activity with those observed in phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) to determine relative potency and assess durability. RESULTS: No safety concerns were identified at any of the dose levels studied. Four weeks after immunization with the ChAd3 vaccine, ZEBOV-specific antibody responses were similar to those induced by rVSV-ZEBOV vaccination, with a geometric mean titer of 752 and 921, respectively. ZEBOV neutralization activity was also similar with the two vaccines (geometric mean titer, 14.9 and 22.2, respectively). Boosting with the MVA vector increased virus-specific antibodies by a factor of 12 (geometric mean titer, 9007) and increased glycoprotein-specific CD8+ T cells by a factor of 5. Significant increases in neutralizing antibodies were seen after boosting in all 30 participants (geometric mean titer, 139; P<0.001). Virus-specific antibody responses in participants primed with ChAd3 remained positive 6 months after vaccination (geometric mean titer, 758) but were significantly higher in those who had received the MVA booster (geometric mean titer, 1750; P<0.001). CONCLUSIONS: The ChAd3 vaccine boosted with MVA elicited B-cell and T-cell immune responses to ZEBOV that were superior to those induced by the ChAd3 vaccine alone. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT02240875.).
BACKGROUND: The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority for control of a future outbreak. METHODS: In this phase 1 study, we administered a single dose of the chimpanzee adenovirus 3 (ChAd3) vaccine encoding the surface glycoprotein of Zaire ebolavirus (ZEBOV) to 60 healthy adult volunteers in Oxford, United Kingdom. The vaccine was administered in three dose levels--1×10(10) viral particles, 2.5×10(10) viral particles, and 5×10(10) viral particles--with 20 participants in each group. We then assessed the effect of adding a booster dose of a modified vaccinia Ankara (MVA) strain, encoding the same Ebola virus glycoprotein, in 30 of the 60 participants and evaluated a reduced prime-boost interval in another 16 participants. We also compared antibody responses to inactivated whole Ebola virus virions and neutralizing antibody activity with those observed in phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) to determine relative potency and assess durability. RESULTS: No safety concerns were identified at any of the dose levels studied. Four weeks after immunization with the ChAd3 vaccine, ZEBOV-specific antibody responses were similar to those induced by rVSV-ZEBOV vaccination, with a geometric mean titer of 752 and 921, respectively. ZEBOV neutralization activity was also similar with the two vaccines (geometric mean titer, 14.9 and 22.2, respectively). Boosting with the MVA vector increased virus-specific antibodies by a factor of 12 (geometric mean titer, 9007) and increased glycoprotein-specific CD8+ T cells by a factor of 5. Significant increases in neutralizing antibodies were seen after boosting in all 30 participants (geometric mean titer, 139; P<0.001). Virus-specific antibody responses in participants primed with ChAd3 remained positive 6 months after vaccination (geometric mean titer, 758) but were significantly higher in those who had received the MVA booster (geometric mean titer, 1750; P<0.001). CONCLUSIONS: The ChAd3 vaccine boosted with MVA elicited B-cell and T-cell immune responses to ZEBOV that were superior to those induced by the ChAd3 vaccine alone. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT02240875.).
Authors: Xiangguo Qiu; Judie B Alimonti; P Leno Melito; Lisa Fernando; Ute Ströher; Steven M Jones Journal: Clin Immunol Date: 2011-08-31 Impact factor: 3.969
Authors: Julie E Ledgerwood; Adam D DeZure; Daphne A Stanley; Emily E Coates; Laura Novik; Mary E Enama; Nina M Berkowitz; Zonghui Hu; Gyan Joshi; Aurélie Ploquin; Sandra Sitar; Ingelise J Gordon; Sarah A Plummer; LaSonji A Holman; Cynthia S Hendel; Galina Yamshchikov; Francois Roman; Alfredo Nicosia; Stefano Colloca; Riccardo Cortese; Robert T Bailer; Richard M Schwartz; Mario Roederer; John R Mascola; Richard A Koup; Nancy J Sullivan; Barney S Graham Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: Bahaa S Malaeb; Thomas A Gardner; Vitaly Margulis; Ling Yang; Jay Y Gillenwater; Leland W K Chung; Gail Macik; Kenneth S Koeneman Journal: Urology Date: 2005-10 Impact factor: 2.649
Authors: Eleanor Barnes; Antonella Folgori; Stefania Capone; Leo Swadling; Stephen Aston; Ayako Kurioka; Joel Meyer; Rachel Huddart; Kira Smith; Rachel Townsend; Anthony Brown; Richard Antrobus; Virginia Ammendola; Mariarosaria Naddeo; Geraldine O'Hara; Chris Willberg; Abby Harrison; Fabiana Grazioli; Maria Luisa Esposito; Loredana Siani; Cinzia Traboni; Ye Oo; David Adams; Adrian Hill; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Paul Klenerman Journal: Sci Transl Med Date: 2012-01-04 Impact factor: 17.956
Authors: Leo Swadling; Stefania Capone; Richard D Antrobus; Anthony Brown; Rachel Richardson; Evan W Newell; John Halliday; Christabel Kelly; Dan Bowen; Joannah Fergusson; Ayako Kurioka; Virginia Ammendola; Mariarosaria Del Sorbo; Fabiana Grazioli; Maria Luisa Esposito; Loredana Siani; Cinzia Traboni; Adrian Hill; Stefano Colloca; Mark Davis; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Paul Klenerman; Eleanor Barnes Journal: Sci Transl Med Date: 2014-11-05 Impact factor: 17.956
Authors: Susanne H Sheehy; Christopher J A Duncan; Sean C Elias; Prateek Choudhary; Sumi Biswas; Fenella D Halstead; Katharine A Collins; Nick J Edwards; Alexander D Douglas; Nicholas A Anagnostou; Katie J Ewer; Tom Havelock; Tabitha Mahungu; Carly M Bliss; Kazutoyo Miura; Ian D Poulton; Patrick J Lillie; Richard D Antrobus; Eleanor Berrie; Sarah Moyle; Katherine Gantlett; Stefano Colloca; Riccardo Cortese; Carole A Long; Robert E Sinden; Sarah C Gilbert; Alison M Lawrie; Tom Doherty; Saul N Faust; Alfredo Nicosia; Adrian V S Hill; Simon J Draper Journal: Mol Ther Date: 2012-10-23 Impact factor: 11.454
Authors: Geraldine A O'Hara; Christopher J A Duncan; Katie J Ewer; Katharine A Collins; Sean C Elias; Fenella D Halstead; Anna L Goodman; Nick J Edwards; Arturo Reyes-Sandoval; Prudence Bird; Rosalind Rowland; Susanne H Sheehy; Ian D Poulton; Claire Hutchings; Stephen Todryk; Laura Andrews; Antonella Folgori; Eleanor Berrie; Sarah Moyle; Alfredo Nicosia; Stefano Colloca; Riccardo Cortese; Loredana Siani; Alison M Lawrie; Sarah C Gilbert; Adrian V S Hill Journal: J Infect Dis Date: 2012-01-24 Impact factor: 5.226
Authors: Katie J Ewer; Geraldine A O'Hara; Christopher J A Duncan; Katharine A Collins; Susanne H Sheehy; Arturo Reyes-Sandoval; Anna L Goodman; Nick J Edwards; Sean C Elias; Fenella D Halstead; Rhea J Longley; Rosalind Rowland; Ian D Poulton; Simon J Draper; Andrew M Blagborough; Eleanor Berrie; Sarah Moyle; Nicola Williams; Loredana Siani; Antonella Folgori; Stefano Colloca; Robert E Sinden; Alison M Lawrie; Riccardo Cortese; Sarah C Gilbert; Alfredo Nicosia; Adrian V S Hill Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh Journal: FEBS Lett Date: 2019-12-11 Impact factor: 4.124
Authors: Selidji T Agnandji; Angela Huttner; Madeleine E Zinser; Patricia Njuguna; Christine Dahlke; José F Fernandes; Sabine Yerly; Julie-Anne Dayer; Verena Kraehling; Rahel Kasonta; Akim A Adegnika; Marcus Altfeld; Floriane Auderset; Emmanuel B Bache; Nadine Biedenkopf; Saskia Borregaard; Jessica S Brosnahan; Rebekah Burrow; Christophe Combescure; Jules Desmeules; Markus Eickmann; Sarah K Fehling; Axel Finckh; Ana Rita Goncalves; Martin P Grobusch; Jay Hooper; Alen Jambrecina; Anita L Kabwende; Gürkan Kaya; Domtila Kimani; Bertrand Lell; Barbara Lemaître; Ansgar W Lohse; Marguerite Massinga-Loembe; Alain Matthey; Benjamin Mordmüller; Anne Nolting; Caroline Ogwang; Michael Ramharter; Jonas Schmidt-Chanasit; Stefan Schmiedel; Peter Silvera; Felix R Stahl; Henry M Staines; Thomas Strecker; Hans C Stubbe; Benjamin Tsofa; Sherif Zaki; Patricia Fast; Vasee Moorthy; Laurent Kaiser; Sanjeev Krishna; Stephan Becker; Marie-Paule Kieny; Philip Bejon; Peter G Kremsner; Marylyn M Addo; Claire-Anne Siegrist Journal: N Engl J Med Date: 2015-04-01 Impact factor: 91.245
Authors: Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas Journal: N Engl J Med Date: 2015-04-01 Impact factor: 91.245